• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
INAHTA member agency stories of engaging, adaptable, and impactful HTA.国际卫生技术评估网络(INAHTA)成员机构关于引人入胜、适应性强且具影响力的卫生技术评估的故事。
Int J Technol Assess Health Care. 2024 Dec 10;41(1):e4. doi: 10.1017/S0266462324004732.
2
INSIGHTS FROM THE FRONT LINES: A COLLECTION OF STORIES OF HTA IMPACT FROM INAHTA MEMBER AGENCIES.一线观察:来自 INAHTA 成员机构的 HTA 影响故事集。
Int J Technol Assess Health Care. 2017 Jan;33(4):409-410. doi: 10.1017/S0266462317001076.
3
Demonstrating the influence of HTA: INAHTA member stories of HTA impact.展示 HTA 的影响:INAHTA 成员的 HTA 影响故事。
Int J Technol Assess Health Care. 2020 Nov 5;37:e8. doi: 10.1017/S0266462320000835.
4
The 'Top 10' Challenges for Health Technology Assessment: INAHTA Viewpoint.十大健康技术评估挑战:INAHTA 观点。
Int J Technol Assess Health Care. 2020;36(1):1-4. doi: 10.1017/S0266462319000825. Epub 2019 Nov 28.
5
Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe.全球卫生技术评估机构对循证审议流程的使用。
Int J Health Policy Manag. 2020 Jan 1;9(1):27-33. doi: 10.15171/ijhpm.2019.72.
6
HTA responsiveness to today's challenges to health systems: a responsible innovation in health perspective.卫生技术评估对当今卫生系统挑战的应对能力:从健康领域负责任创新的视角来看
Int J Technol Assess Health Care. 2025 Mar 3;41(1):e16. doi: 10.1017/S0266462325000121.
7
Oncology drug health technology assessment recommendations: Canadian versus UK experiences.肿瘤学药物健康技术评估建议:加拿大与英国的经验对比
Clinicoecon Outcomes Res. 2014 Jul 16;6:357-67. doi: 10.2147/CEOR.S66309. eCollection 2014.
8
The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies.卫生技术评估中公共价值的体现,以告知资金决策:以澳大利亚国家资金机构为例。
Int J Technol Assess Health Care. 2021 Jan 18;37:e22. doi: 10.1017/S0266462320002238.
9
Development of the International Network of Agencies for Health Technology Assessment.国际卫生技术评估机构网络的发展
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:24-7. doi: 10.1017/S0266462309090370. Epub 2009 Jun 8.
10
Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit.芬兰基于医院的卫生技术评估(HTA):医院与国家卫生技术评估机构合作的案例研究
Health Res Policy Syst. 2016 Apr 5;14:25. doi: 10.1186/s12961-016-0095-2.

本文引用的文献

1
UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update.UroLift 治疗良性前列腺增生症下尿路症状:NICE 医疗技术指导更新。
Appl Health Econ Health Policy. 2022 Sep;20(5):669-680. doi: 10.1007/s40258-022-00735-y. Epub 2022 Jul 18.
2
Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System.从台湾全民健康保险注册系统获得的免疫检查点抑制剂的真实世界结果。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6548-6556. doi: 10.26355/eurrev_202111_27097.
3
Prostatic urethral lift (UroLift): a real-world analysis of outcomes using hospital episodes statistics.前列腺尿道提升术(UroLift):使用医院病例统计数据进行的真实世界疗效分析。
BMC Urol. 2021 Apr 7;21(1):55. doi: 10.1186/s12894-021-00824-5.
4
Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan.台湾免疫检查点抑制剂报销政策及真实世界数据收集的经验教训。
Int J Technol Assess Health Care. 2020 Dec 21;37:e26. doi: 10.1017/S0266462320002160.
5
Demonstrating the influence of HTA: INAHTA member stories of HTA impact.展示 HTA 的影响:INAHTA 成员的 HTA 影响故事。
Int J Technol Assess Health Care. 2020 Nov 5;37:e8. doi: 10.1017/S0266462320000835.
6
Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment.不明原因发育障碍或多发先天性异常的全基因组测序:一项卫生技术评估
Ont Health Technol Assess Ser. 2020 Mar 6;20(11):1-178. eCollection 2020.
7
The 'Top 10' Challenges for Health Technology Assessment: INAHTA Viewpoint.十大健康技术评估挑战:INAHTA 观点。
Int J Technol Assess Health Care. 2020;36(1):1-4. doi: 10.1017/S0266462319000825. Epub 2019 Nov 28.
8
The burden of rare diseases.罕见病的负担。
Am J Med Genet A. 2019 Jun;179(6):885-892. doi: 10.1002/ajmg.a.61124. Epub 2019 Mar 18.
9
Outcomes and Impacts of 10-Year HTA Implementation in Taiwan.台湾十年 HTA 实施的结果和影响。
Int J Technol Assess Health Care. 2019;35(6):441-445. doi: 10.1017/S0266462319000011. Epub 2019 Feb 28.
10
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.非清髓性造血干细胞移植与继续疾病修正治疗对复发缓解型多发性硬化症患者疾病进展的影响:一项随机临床试验。
JAMA. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743.

国际卫生技术评估网络(INAHTA)成员机构关于引人入胜、适应性强且具影响力的卫生技术评估的故事。

INAHTA member agency stories of engaging, adaptable, and impactful HTA.

作者信息

Söderholm Werkö Sophie, Bouchard Sylvie, Romli Erni Z, Li Chunmei, Huang Li-Ying, Pelekanou Charlotte, Elston Lauren, Schuller Tara

机构信息

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.

Institut national d'excellence en santé et en services sociaux, Québec, QC, Canada.

出版信息

Int J Technol Assess Health Care. 2024 Dec 10;41(1):e4. doi: 10.1017/S0266462324004732.

DOI:10.1017/S0266462324004732
PMID:39653604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11729482/
Abstract

Health technology assessment (HTA) agencies assess evidence to support decision making about which technologies to provide and pay for in the health system. HTA impact is understood as the influence that HTA report findings can have in the health system, including impacts on reimbursement decisions, changes to health outcomes, or broader system or societal impacts. The International Network of Agencies for Health Technology Assessment (INAHTA) is a global network of publicly funded HTA agencies. INAHTA's mission, in part, is to advance the impact of HTA to support reimbursement decisions and the optimal use of health system resources. Each year, INAHTA awards the David Hailey Award for Best Impact Story to the member agency that shares the best story, as voted by fellow members, about HTA impact. The impact story sharing program in INAHTA contributes to a deeper understanding of what works well (or not so well) in achieving HTA impact. This paper provides six impact stories from agencies that were finalists for the 2021 and 2022 David Hailey Impact Award for Best Impact Story: the Institut national d'excellence en santé et en services sociaux, the Malaysian Health Technology Assessment Section, Ontario Health, the Center for Drug Evaluation, the National Institute for Health and Care Excellence, and Health Technology Wales. These stories demonstrate that HTA agencies can, in differing ways, effectively support governments in their efforts to place evidence at the centre of decision making.

摘要

卫生技术评估(HTA)机构评估相关证据,以支持关于在卫生系统中提供哪些技术并为之付费的决策。HTA的影响被理解为HTA报告结果在卫生系统中可能产生的影响,包括对报销决策的影响、健康结果的变化,或更广泛的系统或社会影响。国际卫生技术评估机构网络(INAHTA)是一个由公共资助的HTA机构组成的全球网络。INAHTA的部分使命是提升HTA的影响力,以支持报销决策和卫生系统资源的优化利用。每年,INAHTA都会将最佳影响故事大卫·黑利奖授予分享最佳故事的成员机构,该故事由成员投票选出,内容是关于HTA的影响。INAHTA的影响故事分享计划有助于更深入地了解在实现HTA影响方面哪些做法有效(或不太有效)。本文提供了来自六家机构的影响故事,这些机构是2021年和2022年大卫·黑利最佳影响故事奖的入围者:魁北克国家公共卫生与社会服务卓越研究所、马来西亚卫生技术评估部门、安大略省卫生厅、药品评价中心、英国国家卫生与临床优化研究所和威尔士卫生技术评估机构。这些故事表明,HTA机构可以通过不同方式,有效地支持政府将证据置于决策核心的努力。